Related Experiment Video
Updated: Jul 12, 2026
07:20
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Key factors in evaluating potential clinical biomarkers
1Rules Based Medicine, 3300 Duval Road, Austin, TX 78759, USA. mspain@rbmmaps.com
Idrugs : the Investigational Drugs Journal
|September 6, 2007
Summary
Clinical biomarkers require robust validation for patient care, unlike experimental markers. Ensuring consistent sample handling and assay performance is crucial for reliable clinical utility and patient safety.
Area of Science:
- Biomarker Discovery and Validation
- Clinical Diagnostics
- Translational Medicine
Background:
- Clinical biomarkers differ significantly from experimental ones, necessitating distinct development considerations.
- Patient care settings present unique challenges, including uncontrolled variables, unlike controlled experimental environments.
- Biomarkers used in clinical practice must be exceptionally robust due to the absence of control groups for sample handling.
Purpose of the Study:
- To highlight the critical differences between experimental and clinical biomarkers.
- To emphasize the necessity of robustness and reliability for biomarkers in clinical settings.
- To outline key considerations for developing and implementing clinical biomarkers.
Main Methods:
- Comparative analysis of biomarker development pathways for experimental versus clinical use.
- Emphasis on the critical role of sample handling and assay consistency in clinical biomarker validation.
- Discussion of factors influencing clinical biomarker utility, including clinical context and data output formats.
Main Results:
- Clinical biomarkers must demonstrate high robustness to overcome variability inherent in patient care.
- Inconsistent sample handling or assay performance can severely limit a biomarker's clinical utility and potentially endanger patients.
- The development of clinical biomarkers requires careful consideration of samples, assays, clinical context, and data reporting.
Conclusions:
- Robustness is the paramount requirement for any biomarker intended for clinical application.
- Rigorous validation addressing real-world clinical variability is essential for safe and effective biomarker use.
- Successful clinical biomarker implementation depends on addressing practical challenges in sample management, assay execution, and data interpretation.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.